Jawline filler passes safety check in 114-Person trial
NCT ID NCT06562075
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety and effectiveness of Decoria Intense Strong, a filler used to improve the shape of the jawline. 114 adults received the treatment. Doctors found that it safely enhanced jawline contour, with most patients showing noticeable improvement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
114 people
The number who actually took part.
- Started
-
Sep 2024
- Finished
-
Dec 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults ≥18 years, males and females. 2. Able and willing to give written informed consent for participation in the investigation. 3. Treating investigator considers the subject's jaw (including or not including chin) amenable to an improvement of at least 1 grade on GAIS. At least one side with either potential to enhance contouring or moderate to severe loss of jawline definition. The grades do not have to be the same on both sides. 4. Ability to follow study instructions and likely to complete all required visits. Exclusion Criteria: 1. Pregnant or lactating females. 2. Any previous hypersensitivity reaction to any constituent of the Investigational medical device (IMD) or to local anesthetic products. 3. Performed or planned surgery below the nose, permanent implant, injection with fat, and deoxycholic acid that may confound the evaluation of safety and performance of the IMD. 4. Any other intradermal injection, such as semi-permanent fillers or botulinum toxins (no complications are allowed), received in the same injection area within 9 months of the Treatment visit (Visit 1) that may confound the evaluation of safety and performance of the IMD. 5. Has an ongoing episode/relapse, recently diagnosed or newly started medication of an autoimmune disease, as judged by the investigator. 6. Has any chronic or acute skin disease or inflammation (such as pimples, rashes or hives) within or close to the treatment area. 7. Has any treatments (thrombolytics, anticoagulants etc) or disease related to the coagulation system. 8. Subjects that have taken any type of vaccine within two weeks prior injection with the IMD. 9. Patients receiving interferon and ribavirin treatment. 10. Features that may interfere with the visual assessment such as recent cosmetic treatment, scarring, abscess, piercing or tattoo. 11. Participation in a clinical investigation that may affect the safety or performance of this investigation, as judged by the Principal Investigator, or authorized designee. 12. Employees of the study site or the sponsor directly involved with the conduct of the investigation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Jawline contour deficit are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Florakliniken
Stockholm, 113 28, Sweden
-
Göteborg Laser & Estetik
Gothenburg, 411 08, Sweden
-
Inskinity
Gothenburg, 411 07, Sweden
-
Inskinity
Stockholm, 111 28, Sweden
-
Svenska Hudkliniker
Karlstad, 652 25, Sweden
-
Svenska Hudkliniker
Stockholm, Sweden
-
The Faculty
Stockholm, 114 46, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.